Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Evolving Role of Novel Imaging Techniques for Radiotherapy Planning.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024

Same author

The Benefits of a Rapid Access Pathway for Patients Requiring Single Fraction Radiotherapy Treatment: The Cambridge Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024

Same author

Re-irradiation: From Cell Lines to Patients, Filling the (Science) Gap in the Market.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023

Same author

Percutaneous cryoablation for desmoid fibromatosis: initial experience at a UK centre.

Clinical radiology·2022

Same author

Results of a single-arm pilot study of <sup>32</sup>P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy.

ESMO open·2021

Same author

Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).

Gynecologic oncology·2021

Search research articles

Related Experiment Video

Updated: Mar 1, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Systemic Treatments in Soft Tissue Sarcomas.

H Hatcher¹, C Benson², T Ajithkumar¹

¹Cambridge University Hospitals, Cambridge, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))

|May 30, 2017

Summary

Systemic treatment for adult soft tissue sarcoma is evolving. While its use before surgery (neoadjuvant) is experimental and after surgery (adjuvant) inconclusive, chemotherapy can be considered individually for advanced or metastatic cases.

Keywords:

Soft tissue sarcoma systemic therapy targeted agents

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Related Experiment Videos

Last Updated: Mar 1, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Area of Science:

Oncology
Medical treatment of soft tissue sarcoma

Background:

Systematic treatment for adult-type soft tissue sarcoma is undergoing significant evolution.
The application of systemic therapy in the neoadjuvant and adjuvant settings for soft tissue sarcoma requires further investigation.
Current data on adjuvant chemotherapy efficacy remain inconclusive, necessitating careful consideration in clinical practice.

Purpose of the Study:

To review the evolving landscape of systemic treatment for adult-type soft tissue sarcoma.
To discuss the current evidence and clinical considerations for neoadjuvant and adjuvant chemotherapy.
To highlight the established role of systemic therapy in advanced and metastatic disease management.

Main Methods:

Review of current literature and clinical practice guidelines regarding systemic therapy for soft tissue sarcoma.
Analysis of the experimental role of neoadjuvant chemotherapy.
Evaluation of inconclusive data on adjuvant chemotherapy.

Main Results:

Neoadjuvant chemotherapy for soft tissue sarcoma is currently considered experimental.
Data supporting the use of adjuvant chemotherapy in soft tissue sarcoma are inconclusive.
Systemic therapy is well-established for locally advanced and metastatic soft tissue sarcoma.

Conclusions:

Neoadjuvant and adjuvant chemotherapy for soft tissue sarcoma should be considered on an individual basis following multidisciplinary team discussion.
Histology-based treatment approaches are under active investigation for systemic therapy in soft tissue sarcoma.
Ongoing research is crucial for refining treatment strategies in soft tissue sarcoma management.